The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•4 May 2026•

1 min read

ADMA Biologics Gains FDA Approval for ASCENIV Pediatric Label Expansion

Key Facts

1The FDA approved the label expansion for ASCENIV to include pediatric immune compromised patients aged two years and older.

ADMA Biologics has announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for its intravenous immune globulin product, ASCENIV. The new indication allows the treatment to be used for pediatric immune-compromised patients aged two years and older. This regulatory milestone enables the company to market its specialized therapy to a broader demographic, specifically targeting younger children in need of immune support. By expanding the addressable market for one of its core products, ADMA Biologics positions itself for potential revenue growth within the biotechnology sector. The approval underscores the clinical safety and efficacy of the product for vulnerable patient populations, marking a significant step forward for the mid-cap firm's commercial strategy.